Pancreatic Cancer Drug Reduces Tumor
There has been an exciting discovery in the battle against pancreatic cancer in the form of a compound called MM41. According to research and experimentation results, there was an 80% reduction in pancreatic cancer tumor growth when the compound was used to treat mice.
This is certainly good news, and much more so for those who are at risk for acquiring pancreatic cancer or for those who are already diagnosed with it. It is a leading cause of death compared to other forms of cancer and it oftentimes has a poor prognosis even when detected early.
What makes pancreatic cancer deadly is its rapid spread to other parts of the body and there are no suggestive symptoms during its early stages. It is only during its advanced stages that the symptoms are more defined. I think it goes without saying that this is one terrifying disease.
MM41 is a new compound that blocks defective genes by targeting quadruplexes, which are little knots found in DNA, consequently making a gene faulty or defective. On a more technical note, they specifically target two types of genes, namely k-RAS and BCL-2. These two genes are encountered in a majority of pancreatic cancer cases.
Professor Stephen Neidle leads the research at the University College London. They conducted the trial using two groups of eight mice that have pancreatic tumors. They used different doses of the compound for each group and treated the mice twice a week for forty days, while a control group received no treatment at all.
It was noted that the tumors in the group where a higher dose of the MM41 compound was administered decreased by an 80% average. In fact, for two of the subjects, their tumors disappeared altogether without any signs of regeneration after the treatment was stopped. This observation was made within the next 239 days which comprised the remainder of their natural life span, approximately.
When the mice tumors were analyzed, it was confirmed that the compound was indeed able to accomplish what it was thought to do, having been absorbed within the cancer cell's nucleus and effectively inhibiting its propagation. And more good news, there weren't any significant side effects noted and no damage was seen to the mice's organs and tissues.
Professor Neidle said that this could be a very promising alternative in the fight against pancreatic cancer. He's certainly right, and the results speak for themselves. However, he also added that there was still a lot of research left to be done and it could still be a while before human trials will be undertaken.
For now, we can only hope that things continue to go well for this promising new compound and that someday it really will turn out to be the answer we're looking for against pancreatic cancer, one of the deadliest forms of cancer to date. But until then, let's just stick to some simpler solutions like lifestyle changes for the better and looking out for our bodies.